Xenetic Biosciences, Inc. (XBIO)
Nasdaq: XBIO · Pharmaceutical Preparations · Framingham, MA · filing with the SEC since 2011
Filings
280 filings since 2017 beside 83 insider forms · Non-accelerated filer and smaller reporting company · read from EDGAR on Nov 13, 2026Due nextNon-accelerated filer and smaller reporting company
10-K
Annual report for the fiscal year ending Dec 31, 2026Non-accelerated filers and smaller reporting companies have 90 days after the fiscal year ends.
by Mar 31, 2027
10-Q
Quarterly report for the quarter ending Mar 31, 2027Non-accelerated filers and smaller reporting companies have 45 days after the quarter ends; quarter ends are taken to the month end.
by May 15, 2027
A deadline is the latest date the SEC's rules allow for its filer category. It is not a forecast of the day the company files. Last time, the results release (8-K item 2.02) came 44 days after the quarter ended. The proxy statement was last filed Oct 31, 2025.
Filings a yearinsider forms included
9136393028292024
2026 counts to Nov 13, 2026.
Officer or director change (8-K item 5.02): 4 times in the last 36 months, the newest Apr 24, 2026.Auditor change (8-K item 4.01): 1 time in the last 36 months, the newest Apr 10, 2025.SEC letters: 2 in the last 36 months, the newest Oct 30, 2024.
Insider forms (3, 4, 5 and 144) are counted each year but not listed here; the people and their trades are on the Ownership tab.
FiledFormWhat it is, in plain wordsPeriodAsk
Nov 13, 2026
8-K items 2.02, 9.01
Results released · Current reportThe SI's read Xenetic Biosciences reported a third quarter net loss of about $1.7 million against about $0.5 million a year earlier, as royalty revenue fell 29% to about $0.7 million and general and administrative costs rose 138% on deal advisory fees. Cash fell to about $5.8 million from about $7.9 million at the end of 2025, and the company said it expects its all stock exchange with Santersus AG to close in the first quarter of 2027, subject to a shareholder vote. The tag is concerning because the loss widened and cash shrank while the company depends on completing the deal.
Sep 16, 2026
8-K items 1.01, 3.02, 7.01, 9.01
Major agreement signed; Shares sold without registration; Investor disclosure (Regulation FD) · Current report
Sep 14, 2026
Oct 14, 2025
8-K items 1.01, 8.01, 9.01
Major agreement signed; Other event · Current report
Oct 10, 2025
40 of 280 shown
Every row opens the filing on EDGAR. The plain words are the site's own for each form and each 8-K item; the complete history, insider forms included, is on EDGAR.